Skip NavigationSkip to Content

Retrospective family study of childhood medulloblastoma

  1. Author:
    Ng, D.
    Stavrou, T.
    Liu, L.
    Taylor, M. D.
    Gold, B.
    Dean, M.
    Kelley, M. J.
    Dubovsky, E. C.
    Vezina, G.
    Nicholson, H. S.
    Byrne, J.
    Rutka, J. T.
    Hogg, D.
    Reaman, G. H.
    Goldstein, A. M.
  2. Author Address

    NCI, DCEG, DHHS, Genet Epidemiol Branch,NIH, Bethesda, MD 20892 USA. Childrens Natl Med Ctr, Dept Hematol Oncol, Washington, DC 20010 USA. Univ Toronto, Div Med & Med Biophys, Toronto, ON, Canada. Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada. NCI, CRC, NIH, DHHS,Lab Genom Divers, Frederick, MD 21701 USA. Duke Univ, Dept Med, Durham, NC USA. Childrens Natl Med Ctr, Dept Diagnost Imaging & Radiol, Washington, DC 20010 USA Ng, D, NCI, NIH, 6120 Executive Pl,Room 7005, Rockville, MD 20852 USA
    1. Year: 2005
    2. Date: MAY 1
  1. Journal: American Journal of Medical Genetics Part A
    1. 134A
    2. 4
    3. Pages: 399-403
  2. Type of Article: Article
  1. Abstract:

    Medulloblastoma. is the most common malignant central nervous system tumor of childhood and can occur sporadically or in association with inherited cancer susceptibility syndromes such as the nevoid basal cell carcinoma syndrome (NBCCS). To determine whether an association existed between the risk of developing medulloblastoma and undiagnosed syndromes, we retrospectively reviewed clinical data on 33 patients with medulloblastoma from a single institution and compared them with their unaffected relatives (n = 46). Six patients had tumors showing desmoplastic histology. Two of the six met diagnostic criteria for NBCCS. One NBCCS patient had a missense mutation of patched-1 (PTCH1); the other had no identifiable PTCH1 mutation. Two patients with isolated desmoplastic medulloblastoma. had an insertion and splice site mutation, respectively, in suppressor of fused (SUFU). All patients with nondesmoplastic medulloblastoma histology received molecular testing for SUFU. None of these patients had an identifiable mutation in PTCH1 or SUFU. We performed a clinical evaluation for Greig cephalopolysyndactyly syndrome (GCPS) in four medulloblastoma families, who exhibited macrocephaly as the only finding consistent with the diagnosis of GCPS. Molecular analysis of GLI3 in these four families was negative. There was a paucity of clinical findings among the majority of medulloblastoma patients in this study group to suggest a definable cancer genetic syndrome. We conclude that clinically recognizable syndromes are uncommon among patients with medulloblastoma, however, PTCH1 and SUFU mutations are present at a low but significant frequency. Published 2005 Wiley-Liss, Inc.(dagger)

    See More

External Sources

  1. WOS: 000228758400009

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel